Assembly Biosciences Inc (ASMB)

2.170
+0.010(+0.46%)
After Hours
2.120
-0.050(-2.304%)
- Real-time Data
  • Volume:
    289,805
  • Day's Range:
    2.100 - 2.230
  • 52 wk Range:
    1.320 - 3.940

ASMB Overview

Prev. Close
2.16
Day's Range
2.1-2.23
Revenue
6.25M
Open
2.23
52 wk Range
1.32-3.94
EPS
-2.77
Volume
289,805
Market Cap
104.63M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
480,425
P/E Ratio
-0.805
Beta
0.728
1-Year Change
-38.18%
Shares Outstanding
48,216,473
Next Earnings Date
Nov 10, 2022
What is your sentiment on Assembly Biosciences?
or
Market is currently closed. Voting is open during market hours.

Assembly Biosciences Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Assembly Biosciences Inc Analysis

Assembly Biosciences Inc Company Profile

Assembly Biosciences Inc Company Profile

Employees
102

Assembly Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of therapeutics targeting hepatitis B virus (HBV) and other viral diseases. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H3733, and ABI-4334. Vebicorvir (VBR) is its lead core inhibitor product candidate, which is licensed from Indiana University. VBR is developed for the treatment of the treatment of patients with chronic HBV infection. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The Company is conducting Phase I study of 3733. The Company’s research and development programs pursue multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsSellBuyStrong BuyStrong BuyStrong Sell
SummaryNeutralStrong BuyStrong BuyStrong BuyStrong Sell
  • it's under their cash balance...
    1
    • Woke up?
      0
      • looks like, there's an issue here...
        0
        • ?
          0
          • Si sube bien y si baja ps mejor todavi porque recompro
            0
            • New good position 4.10 🚀
              1
              • I’m in now. I believe it! 💪🏼
                0
                • Alberto CasseràSure...no further, than 2023
                  0
                • 300-400% during 2-3 years is not bad...patience and divresification are strength...mistakes also...we’ll see whats going on :)
                  0
                • well said, however 10-15x is possible here with a successful cure approval...Arbutus technology is the key. If that's not help, then nothing...
                  0
              • Long and bumpy road ahead...best case is a Phase 2 approval for this year.
                0
                • Any rumors? Who’s in?
                  0
                  • what happened
                    0
                    • HBV trial failed.
                      0